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ABSTRACT
Objective We studied evolving antithrombotic therapy
patterns in patients with newly diagnosed non-valvular
atrial ﬁbrillation (AF) and ≥1 additional stroke risk factor
between 2010 and 2015.
Methods 39 670 patients were prospectively enrolled
in four sequential cohorts in the Global Anticoagulant
Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF):
cohort C1 (2010–2011), n=5500; C2 (2011–2013),
n=11 662; C3 (2013–2014), n=11 462; C4 (2014–
2015), n=11 046. Baseline characteristics and
antithrombotic therapy initiated at diagnosis were
analysed by cohort.
Results Baseline characteristics were similar across
cohorts. Median CHA2DS2-VASc (cardiac failure,
hypertension, age ≥75 (doubled), diabetes, stroke
(doubled)-vascular disease, age 65–74 and sex category
(female)) score was 3 in all four cohorts. From C1 to C4,
the proportion of patients on anticoagulant (AC) therapy
increased by almost 15% (C1 57.4%; C4 71.1%). Use
of vitamin K antagonist (VKA)±antiplatelet (AP) (C1
53.2%; C4 34.0%) and AP monotherapy (C1 30.2%;
C4 16.6%) declined, while use of non-VKA oral ACs
(NOACs)±AP increased (C1 4.2%; C4 37.0%). Most
CHA2DS2-VASc ≥2 patients received AC, and this
proportion increased over time, largely driven by NOAC
prescribing. NOACs were more frequently prescribed than
VKAs in men, the elderly, patients of Asian ethnicity,
those with dementia, or those using non-steroidal anti-
inﬂammatory drugs, and current smokers. VKA use was
more common in patients with cardiac, vascular, or renal
comorbidities.
Conclusions Since NOACs were introduced, there has
been an increase in newly diagnosed patients with AF at
risk of stroke receiving guideline-recommended therapy,
predominantly driven by increased use of NOACs and
reduced use of VKA±AP or AP alone.
Trial registration number NCT01090362; Pre-results.
INTRODUCTION
Atrial ﬁbrillation (AF) is associated with a ﬁvefold
increase in stroke risk.1 Strokes associated with AF
have a poorer prognosis compared with non-AF
stroke.2 Evidence-based guidelines for stroke pre-
vention in AF recommend anticoagulant (AC)
therapy for patients with additional stroke risk
factors,3–5 but AC therapy is underused in eligible
patients.6 Furthermore, data from registries suggest
that AC therapy is underused in patients at high
stroke risk and potentially overused in those at low
stroke risk.7–11
The most recent European and North American
guidelines for the management of AF incorporate
recommendations on using non-vitamin K antago-
nist oral ACs (NOACs) as an alternative to vitamin
K antagonists (VKAs).3–5 In the present study, the
evolving patterns of antithrombotic therapy were
investigated using data from a large, prospective,
global cohort study of patients with newly diag-
nosed non-valvular AF in different countries, geo-
graphic regions, care settings, and in patients at
different levels of stroke and bleeding risks.
METHODS
Study design and participants
The Global Anticoagulant Registry in the
FIELD-Atrial Fibrillation (GARFIELD-AF) is an
ongoing, prospective, observational, worldwide
study of adults with recently diagnosed non-
valvular AF from 1215 sites in 35 countries. The
study design has been described previously.12
Brieﬂy, men and women aged ≥18 years with non-
valvular AF diagnosed according to standard local
procedures within the previous 6 weeks and ≥1
additional risk factor for stroke as judged by the
investigator are eligible. These risk factors are not
prespeciﬁed in the protocol, nor are they limited to
the components of existing risk stratiﬁcation
schemes. Patients with a transient reversible cause
of AF and those for whom follow-up is not envi-
saged or possible are excluded. Enrolment takes
place in ﬁve independent, sequential cohorts. To
minimise recruitment bias, investigator sites were
selected randomly from representative care settings
in each participating country and consecutive
patients were enrolled. Sample size calculations are
based on the 95% conﬁdence intervals for estimates
of each of the registry endpoints.12
This paper reports cross-sectional data at baseline
including treatment patterns before and after the
introduction of NOACs, for cohorts 1–4 (cohort 1:
March 2010 to October 2011; cohort 2: August
2011 to June 2013; cohort 3: April 2013 to
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October 2014; cohort 4: March 2014 to July 2015), and has
been written according to the STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology) statement.
Data collection
The electronic case report form (eCRF) was designed by
Dendrite Clinical Systems Ltd (Henley-on-Thames, UK).
Oversight of operations and data management was conducted
by the sponsor and coordinating centre (Thrombosis Research
Institute—TRI, London, UK), with support from Quintiles
(Durham, North Carolina, USA), The University of Birmingham
Department of Primary Care Clinical Sciences (Birmingham,
UK), Thrombosis Research Group—Brigham and Women’s
Hospital (Boston, Massachusetts, USA), and AIXIAL (Paris,
France). The GARFIELD-AF protocol requires source data veri-
ﬁcation of 20% of eCRFs, an electronic audit trail for all data
modiﬁcations, and additional audit of critical variables.12 Data
for the analysis in this report were extracted from the study
database on 3 August 2015.
Deﬁnitions
The term AC includes VKAs and NOACs. The term NOAC
includes oral direct factor Xa inhibitors (FXaIs) and oral direct
thrombin inhibitors (DTIs). Vascular disease was deﬁned as
peripheral artery disease and/or coronary artery disease (CAD)
with a history of acute coronary syndromes. Hypertension was
deﬁned as a documented history of hypertension or blood pres-
sure >140/90 mm Hg. Chronic kidney disease (CKD) was
classiﬁed according to the National Kidney Foundation’s Kidney
Disease Outcomes Quality Initiative (NKF KDOQI) guide-
lines:13 moderate-to-severe includes stages III to V; none or
mild includes all other patients. Congestive heart failure (CHF)
was deﬁned as a history of CHF for patients in cohorts C1 and
C2; from C3 onwards there was a protocol amendment and in
these cohorts, CHF consists of current or prior history of CHF.
Figure 1 Antithrombotic treatment at diagnosis by cohort. The total
population represented by n excludes unknowns. AP, antiplatelet; DTI,
direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, vitamin K
antagonist.
Table 1 Baseline characteristics of patients in cohorts 1 to 4
Variable
Cohort 1
2010–2011
(n=5500)
Cohort 2
2011–2013
(n=11 662)
Cohort 3
2013–2014
(n=11 462)
Cohort 4
2014–2015
(n=11 046)
Female, n/N (%) 2402/5500 (43.7) 5116/11 662 (43.9) 5191/11 462 (45.3) 4870/11 046 (44.1)
Age at diagnosis, years, mean (SD) 69.8 (11.5) 69.8 (11.4) 69.6 (11.4)a 69.6 (11.7)
Ethnicity, n/N (%)
Caucasian/Hispanic/Latino 3691/5500 (67.1) 8647/11 662 (74.1) 7896/11 462 (68.9) 7050/11 046 (63.8)
Asian 1589/5500 (28.8) 2392/11 662 (20.5) 3175/11 462 (27.7) 3574/11 046 (32.4)
Other 68/5500 (1.2) 244/11 662 (2.1) 147/11 462 (1.3) 239/11 046 (2.2)
Unwilling to declare 152/5500 (2.8) 379/11 662 (3.2) 244/11 462 (2.1) 183/11 046 (1.7)
Medical history, n/N (%)
CHF 1026/5498 (18.7) 2506/11 662 (21.5) 2206/11 462 (19.2) 2128/11 046 (19.3)
CAD 1059/5498 (19.3) 2357/11 662 (20.2) 2495/11 462 (21.8) 2428/11 046 (22.0)
ACS 553/5498 (10.1) 1061/11 659 (9.1) 1258/11 257 (11.2) 1281/10 884 (11.8)
Vascular disease 847/5498 (15.4) 1653/11 662 (14.2) 1828/11 462 (15.9) 1789/11 046 (16.2)
Systemic embolism 35/5498 (0.6) 74/11 652 (0.6) 85/11 383 (0.7) 78/10 981 (0.7)
Stroke/TIA 727/5498 (13.2) 1459/11 662 (12.5) 1236/11 462 (10.8) 1219/11 046 (11.0)
Bleeding 172/5498 (3.1) 325/11 651 (2.8) 283/11 400 (2.5) 262/10 995 (2.4)
History of hypertension 4224/5498 (76.8) 9172/11 662 (78.6) 8761/11 419 (76.7) 8224/11 004 (74.7)
Diabetes mellitus 1215/5498 (22.1) 2535/11 662 (21.7) 2457/11 462 (21.4) 2443/11 046 (22.1)
Moderate-to-severe CKD* 495/5497 (9.0) 1265/11 662 (10.8) 1209/11 462 (10.5) 1104/11 045 (10.0)
Risk scores
CHA2DS2-VASc, median (Q1–Q3) 3 (2–4)
b 3 (2–4)c 3 (2–4)d 3 (2–4)e
CHA2DS2-VASc, 0–1, n/N (%) 815/5406 (15.1) 1531/11 293 (13.6) 1666/11 252 (14.8) 1700/10 830 (15.7)
HAS-BLED, median (Q1–Q3)† 1 (1–2)f 1 (1–2)g 1 (1–2)h 1 (1–2)i
HAS-BLED, 0–2, n/N (%)† 3109/3561 (87.3) 6321/7302 (86.6) 7650/8584 (89.1) 7824/8654 (90.4)
a1 patient missing; b94 patients missing; c369 patients missing; d210 patients missing; e216 patients missing; f1939 patients missing; g4360 patients missing; h2878 patients missing;
i2392 patients missing.
ACS, acute coronary syndrome; CAD, coronary artery disease; CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74
and sex category (female); CHF, congestive heart failure; CKD, chronic kidney disease; NKF KDOQI, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative; TIA,
transient ischaemic attack.
*Includes NKF KDOQI stages III–V.
†‘modified’ HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each).
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Table 2 Baseline characteristics of patients in cohort 1 to cohort 4 by antithrombotic treatment type
Variable None AP alone AC+AP or AP alone AC+AP NOAC+AP VKA+AP AC±AP NOAC alone VKA alone
N 4802 8714 14 309 5595 1656 3939 25 680 7244 12 841
Female, n (%) 2135 (44.5) 3774 (43.3) 5957 (41.6) 2183 (39.0) 656 (39.6) 1527 (38.8) 11 449 (44.6) 3267 (45.1) 5999 (46.7)
Age at diagnosis, years, mean (SD) 66.8 (13.5) 68.7 (12.1)a 69.4 (11.5)a 70.5 (10.4) 71.2 (10.5) 70.3 (10.3) 70.6 (10.7) 70.7 (10.9) 70.6 (10.8)
Medical history, n (%)
CAD 494 (10.3)b 2834 (32.5) 5139 (35.9) 2305 (41.2) 708 (42.8) 1597 (40.5) 4883 (19.0) 857 (11.8) 1721 (13.4)
Vascular disease 358 (7.5)b 1865 (21.4) 3628 (25.4) 1763 (31.5) 532 (32.1) 1231 (31.3) 3810 (14.8) 682 (9.4) 1365 (10.6)
Systemic embolism 14 (0.3)b 34 (0.4) 96 (0.7) 62 (1.1) 19 (1.2) 43 (1.1) 216 (0.8) 39 (0.5) 115 (0.9)
Stroke 202 (4.2)b 665 (7.7) 1316 (9.2) 651 (11.7) 178 (10.8) 473 (12.0) 2162 (8.4) 508 (7.0) 1003 (7.8)
Bleeding 221 (4.6)b 301 (3.5) 438 (3.1) 137 (2.5) 37 (2.2) 100 (2.5) 492 (1.9) 150 (2.1) 205 (1.6)
Hypertension 3439 (71.6)b 7007 (80.4) 11 787 (82.4) 4780 (85.4) 1403 (84.7) 3377 (85.7) 21 345 (83.1) 5831 (80.5) 10 734 (83.6)
Diabetes mellitus 831 (17.3)b 1816 (20.8) 3533 (24.7) 1717 (30.7) 492 (29.7) 1225 (31.1) 5884 (22.9) 1354 (18.7) 2813 (21.9)
Moderate-to-severe CKD* 371 (7.7)b 826 (9.5)a 1581 (11.0)a 755 (13.5) 208 (12.6) 547 (13.9) 2818 (11.0)a 677 (9.3) 1386 (10.8)a
Risk scores
CHA2DS2-VASc, median (Q1–Q3) 3.0 (1.0–4.0)
c 3.0 (2.0–4.0)d 3.0 (2.0–4.0)e 4.0 (3.0–5.0)f 4.0 (3.0–5.0)g 4.0 (3.0–5.0)h 3.0 (2.0–4.0)i 3.0 (2.0–4.0)j 3.0 (2.0–4.0)k
CHA2DS2-VASc, 0–1, n (%) 1212 (26.5) 1457 (17.1) 1902 (13.5) 445 (8.1) 137 (8.3) 308 (7.9) 2988 (11.9) 1079 (15.1) 1464 (11.7)
HAS-BLED, median (Q1–Q3)† 1.0 (0.0–1.0)l 2.0 (1.0–2.0)m 2.0 (1.0–2.0)n 2.0 (2.0–3.0)o 2.0 (2.0–2.0)p 2.0 (1.0–3.0)q 1.0 (1.0–2.0)r 1.0 (1.0–2.0)s 1.0 (1.0–2.0)t
HAS-BLED, 0–2, n (%)† 2984 (94.2) 4742 (80.0) 7718 (78.0) 2976 (75.0) 911 (76.2) 2065 (74.5) 16 865 (90.4) 5271 (95.0) 8618 (94.4)
a1 patient missing; b2 patients missing; c225 patients missing; d175 patients missing; e244 patients missing; f69 patients missing; g15 patients missing; h54 patients missing; i481 patients missing; j116 patients missing; k296 patients missing; l1634
patients missing; m2787 patients missing; n4413 patients missing; o1626 patients missing; p460 patients missing; q1166 patients missing; r7032 patients missing; s1697 patients missing; t3709 patients missing.
AC, anticoagulant; AP, antiplatelet; CAD, coronary artery disease; CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female); CKD, chronic kidney disease; NKF
KDOQI, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
*Includes NKF KDOQI stages III–V.
†‘modified’ HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each).
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Ethics statement
Independent ethics committee and hospital-based institutional
review board approvals were obtained, as necessary, for the
registry protocol. The registry is being performed in accordance
with the principles of the Declaration of Helsinki, local regula-
tory requirements, and the International Conference on
Harmonisation–Good Pharmacoepidemiological and Clinical
Practice guidelines. All patients gave written informed consent
to participate.
Statistical analysis
The analysis provides descriptive statistics to summarise data
patterns. Continuous variables are expressed as mean±SD and
categorical variables as frequency and percentage. Treatment
patterns were analysed by cohort, by cohort and
CHA2DS2-VASc (cardiac failure, hypertension, age ≥75
(doubled), diabetes, stroke (doubled)-vascular disease, age
65–74 and sex category (female)) score,14 and by cohort and
‘modiﬁed’ HAS-BLED (hypertension, abnormal renal/liver func-
tion (1 point each), stroke, bleeding history or predisposition,
labile international normalised ratios, elderly (>65), drugs/
alcohol concomitantly (1 point each)) score15 (ﬂuctuations in
international normalised ratios were not collected). The risk
scores were calculated retrospectively. NOAC use (relative to
VKA) was analysed according to patient characteristics,
comorbidities, and cohort. Patients in cohorts C2, C3, and C4
using VKA or NOACs were included in the analysis. We
removed patients in C1, since NOACs were not globally avail-
able during this time period. Adjusted odds ratios were esti-
mated using a logistic model based on the following variables:
gender, age group, race, smoking, CHF, hypertension, diabetes,
CAD, vascular disease, dementia, moderate-to-severe CKD, non-
steroidal anti-inﬂammatory drug (NSAID) usage, history of
bleeding, previous stroke/transient ischaemic attack (TIA)/sys-
temic embolism (SE), and cohort. Multiple Imputation by
Chained Equations (MICE) was used to ﬁll in missing values,
creating ﬁve complete datasets.16 17 First-degree interaction
between baseline characteristics and time (cohort) or between
comorbidities and time (cohort) were tested using likelihood
ratio tests. Only signiﬁcant interactions were included in the
ﬁnal model.
Both SAS V.9.4 (SAS Institute Inc, Cary, North Carolina,
USA) and Stata Statistical Software: Release 14 (StataCorp,
College Station, Texas, USA) were used for the data analysis.
RESULTS
Study population
Between March 2010 and July 2015, 39 670 patients were
enrolled in four sequential cohorts: C1 (2010–2011), n=5500;
C2 (2011–2013), n=11 662; C3 (2013–2014), n=11 462; C4
(2014–2015), n=11 046. Baseline characteristics across the four
cohorts were similar, although C3 and C4 had a slightly lower
prevalence of prior stroke/TIA (table 1).
Antithrombotic therapy use by cohort
Figure 1 shows the prescribing patterns at diagnosis of AF in all
four cohorts. The proportion of patients on AC therapy at diag-
nosis, with or without an antiplatelet (AP) agent, increased from
C1 to C4. This rise was due to increasing use of NOACs, with
or without AP, and was greater for FXaIs than for DTI. At the
same time, there was a decline in the use of VKA, with or
without AP, as well as AP therapy alone, while the proportion of
patients not receiving antithrombotic therapy remained
unchanged. Table 2 shows the baseline characteristics for all
patients by treatment group. Patients receiving no treatment
were generally younger and healthier, with a lower incidence of
comorbidities, and had lower CHA2DS2-VASc and HAS-BLED
scores.
Table 3 shows the baseline characteristics of patients on NOACs
by cohort. Patients treated early after the introduction of NOACs
(C1) were more likely than those in later cohorts to suffer from
signiﬁcant underlying disease such as CAD, vascular disease, CKD,
Table 3 Baseline characteristics of patients on NOACs by cohort
Variable Cohort 1 2010–2011 Cohort 2 2011–2013 Cohort 3 2013–2014 Cohort 4 2014–2015
N 224 1611 3000 4065
Female, n (%) 102 (45.5) 703 (43.6) 1351 (45.0) 1767 (43.5)
Age at diagnosis, years, mean (SD) 70.9 (12.5) 70.5 (11.1) 70.8 (10.7) 70.9 (10.7)
Medical history, n (%)
CAD 62 (27.7) 254 (15.8) 518 (17.3) 731 (18.0)
Vascular disease 59 (26.3) 187 (11.6) 381 (12.7) 587 (14.4)
Systemic embolism 2 (0.9) 15 (0.9) 12 (0.4) 29 (0.7)
Stroke 19 (8.5) 163 (10.1) 190 (6.3) 314 (7.7)
Bleeding 13 (5.8) 32 (2.0) 56 (1.9) 86 (2.1)
Hypertension 175 (78.1) 1316 (81.7) 2464 (82.1) 3279 (80.7)
Diabetes mellitus 61 (27.2) 321 (19.9) 614 (20.5) 850 (20.9)
Moderate-to-severe CKD* 40 (17.9) 158 (9.8) 307 (10.2) 380 (9.3)
Risk scores
CHA2DS2-VASc, median (Q1–Q3) 4.0 (2.0–5.0)
a 3.0 (2.0–4.0)b 3.0 (2.0–4.0)c 3.0 (2.0–4.0)d
CHA2DS2-VASc, 0–1, n (%) 29 (13.0) 209 (13.2) 407 (13.8) 571 (14.2)
HAS-BLED, median (Q1–Q3)† 2.0 (1.0–2.0)e 1.0 (1.0–2.0)f 1.0 (1.0–2.0)g 1.0 (1.0–2.0)h
HAS-BLED, 0–2, n (%)† 130 (78.8) 956 (89.8) 2132 (92.2) 2964 (92.6)
a1 patient missing; b32 patients missing; c41 patients missing; d57 patients missing; e59 patients missing; f547 patients missing; g687 patients missing; h864 patients missing.
CAD, coronary artery disease; CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female); CKD,
chronic kidney disease; NKF KDOQI, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant.
*Includes NKF KDOQI stages III–V.
†‘modified’ HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each).
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and diabetes. Analysis of the baseline characteristics of 20 167
patients in the later cohorts (C2, C3, and C4) who were prescribed
either VKA or NOACs found that NOAC use was more frequent
than VKA use in men, patients of Asian ethnicity, the elderly,
patients with dementia, those using NSAIDs, and current smokers
(table 4). VKA use was more common in patients with cardiac, vas-
cular, or renal comorbidities.
Antithrombotic therapy use according to risk score
Use of antithrombotic therapy stratiﬁed by CHA2DS2-VASc
score and cohort is shown in ﬁgure 2. Regardless of cohort, the
proportion of patients on AC therapy increased with
CHA2DS2-VASc score. Although the highest levels of anticoagu-
lation were observed in patients with a CHA2DS2-VASc score
≥2, the increase in anticoagulation from C1 to C4 was greatest
in patients with a score of 0. NOAC prescribing increased
between C1 and C4 in all CHA2DS2-VASc score strata.
Stratifying treatment by HAS-BLED score (ﬁgure 3), the pro-
portion of patients on AC therapy decreased with increasing
score, especially beyond a score of 2. In contrast, higher
HAS-BLED scores were associated with a greater proportion of
patients on AP therapy alone or in combination with an AC. As
the HAS-BLED score increased, the proportion of patients on
no treatment rose.
DISCUSSION
Data from the GARFIELD-AF cohorts collected over the past
5 years show a pronounced change in the pattern of antithrom-
botic therapy prescribing in patients with newly diagnosed AF.
The use of AC therapy has increased and exceeds 70% in the
most recent cohort. This change is predominantly due to
increasing use of NOACs. Thromboprophylaxis with AP and
VKA therapies alone and in combination has declined.
This paradigm shift in prescribing practice has been driven in
part by the availability of NOACs, but also the realisation that
APs are barely effective compared with ACs. Evaluating the pro-
fessional society guidelines published over the last 5 years (espe-
cially relating to AP therapy),3 4 18–22 it is notable that the
Japanese guidelines, for example, no longer recommend AP for
stroke prevention in patients with AF. European Society of
Cardiology and National Institute for Health and Care
Excellence (NICE) guidelines also restrict the use of aspirin and
other AP therapies for patients who refuse anticoagulation.
American College of Cardiology/American Heart Association
and Canadian guidelines have curtailed their recommendations
on the use of these agents.4 21 22
Changes in AC therapy have occurred despite initial reluc-
tance on the part of healthcare payers due to the greater cost of
NOAC medication compared with VKA or AP therapy.
However, the evidence suggests that long-term therapy with
NOACs may be cost-effective compared with VKA treat-
ment,23 24 primarily due to lower monitoring costs and reduced
numbers of patients with strokes and SE.
CHA2DS2-VASc score analysis showed an increase in the use
of NOAC therapy at all levels of risk, including those patients
with a score of 0. While this may indicate some level of over-
treatment, it should be noted that the patients with AF recruited
into GARFIELD-AF were judged by their physician to have at
least one additional risk factor for stroke. Patients may also have
been prescribed ACs for transient purposes such as cardiover-
sion or AF ablation. HAS-BLED score analysis found that AC
prescribing diminished as bleeding risk increased, and a surpris-
ingly high frequency of AP therapy alone or combined with ACs
was still prescribed.
Notably, we have previously shown that there are no gender
differences in the treatment patterns of patients (in C1 and
C2).25 Patients treated early after the introduction of NOACs
(cohort C1) were more likely than those in later cohorts to
suffer from signiﬁcant underlying disease. Analysis of the later
cohorts found that NOACs were more frequently used than
VKAs in the elderly and in those with dementia or taking
NSAIDs, perhaps because of their ease of use and the perceived
lower bleeding risk. The preferential use of NOACs in patients
of Asian ethnicity may have been an attempt to lower the inci-
dence of intracranial haemorrhage. A higher frequency of
Table 4 Use of NOACs in relation to baseline characteristics for
patients on AC at baseline (n=20 167)
Variable OR‡ (95% CI)
Gender
Female 1
Male 1.08 (1.01 to 1.15)
Ethnicity
Caucasian/Hispanic/Latino 1
Asian 1.28 (1.19 to 1.37)
Other 1.08 (0.87 to 1.35)
Age, years
65 1
65–80 1.10 (1.02 to 1.18)
80–85 1.19 (1.08 to 1.32)
>85 1.32 (1.16 to 1.50)
Medical history*
CHF 0.94 (0.87 to 1.01)
Hypertension (history or >140/90 mm Hg) 0.90 (0.83 to 0.97)
Diabetes 0.82 (0.77 to 0.88)
CAD 0.85 (0.77 to 0.94)
Vascular disease 0.87 (0.79 to 0.97)
Dementia 1.46 (1.13 to 1.88)
Moderate-to-severe CKD† 0.84 (0.76 to 0.92)
NSAID usage 1.27 (1.06 to 1.53)
Bleeding 1.19 (0.96 to 1.48)
Smoking
Never 1
Ex-smoker 1.05 (0.98 to 1.13)
Current smoker 1.16 (1.05 to 1.29)
Previous stroke/TIA/SE (reference: no previous stroke/TIA/SE)
In cohort 2 (2011–2013) 1.08 (0.91 to 1.28)
In cohort 3 (2013–2014) 0.76 (0.65 to 0.89)
In cohort 4 (2014–2015) 0.95 (0.82 to 1.10)
Patients without stroke/TIA/SE
Cohort 2 (2011–2013) 1
Cohort 3 (2013–2014) 2.33 (2.14 to 2.53)
Cohort 4 (2014–2015) 3.82 (3.52 to 4.15)
Patients with previous stroke/TIA/SE
Cohort 2 (2011–2013) 1
Cohort 3 (2013–2014) 1.64 (1.32 to 2.03)
Cohort 4 (2014–2015) 3.37 (2.74 to 4.15)
*Reference group is patients with no medical history.
†Includes NKF KDOQI stages III to V; none or mild (reference group) includes all other
patients.
‡An OR >1 implies that NOACs are more frequent than VKAs, while an OR <1 means
that VKAs are more frequent than NOACs. Only the interaction between cohort and
stroke/TIA/SE was statistically significant (p=0.01).
AC, anticoagulant; CAD, coronary artery disease; CHF, congestive heart failure; CKD,
chronic kidney disease; NKF KDOQI, National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant;
NSAID, non-steroidal anti-inflammatory drug; SE, systemic embolism; TIA, transient
ischaemic attack; VKA, vitamin K antagonist.
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patients with hypertension, CAD, and diabetes was prescribed
VKAs, possibly combined with AP therapy, since experience
with the combination of NOAC and AP is limited.26 Patients
with CKD were more likely to receive VKAs, presumably
because of the moderate-to-high dependency of NOACs on
renal elimination. It appears that, despite compelling evidence
for the use of NOACs in secondary prevention,27–30 prescribers
remain relatively wary of NOAC thromboprophylaxis in patients
with prior thromboembolic events, predominantly stroke.
The acceptance of AC therapy in AF among physicians is a
positive step. However, there has been no decrease in the pro-
portion of patients that receive no antithrombotic treatment,
which remains at about 10% of the population. This population
includes some patients at high thromboembolic risk, with low
HAS-BLED scores, for whom anticoagulation would seem to be
appropriate.
GARFIELD-AF provides a unique picture of prescribing at
the end of the VKA-only era, showing the global increase in
NOAC prescribing. Our ﬁndings are strengthened by protocol-
mandated source data veriﬁcation of 20% of eCRFs and central
monitoring, ensuring high data quality. A limitation of this
study is that only global patterns of antithrombotic therapy
were investigated. Regional differences in prescribing trends
were not taken into account, nor was the rate of NOAC
approvals across each region. Comorbidities were also likely
confounders, which were not fully assessed in this analysis.
CONCLUSION
Since the introduction of NOACs, newly diagnosed at-risk
patients with AF are more often receiving guideline-recom-
mended therapy, driven by increased use of NOACs and less
treatment with AP and VKA therapies.
Figure 2 Antithrombotic treatment at diagnosis by CHA2DS2-VASc score and cohort, for patients with a score of 0, 1, and ≥2. The total
population represented by n excludes unknowns. Patients with missing CHA2DS2-VASc score: C1 94; C2 369; C3 210; C4 216. AP, antiplatelet;
CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female);
DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, vitamin K antagonist.
Figure 3 Antithrombotic treatment
at diagnosis by HAS-BLED score,* for
patients with a score of 0, 1, 2, and
≥3, in all cohorts combined. The total
population represented by n excludes
unknowns. Patients with missing
HAS-BLED score: C1 1939; C2 4360;
C3 2878; C4 2392. AP, antiplatelet;
DTI, direct thrombin inhibitor; FXaI,
factor Xa inhibitor; *‘modiﬁed’ HAS-
BLED, hypertension, abnormal renal/
liver function (1 point each), stroke,
bleeding history or predisposition,
elderly (>65), drugs/alcohol
concomitantly (1 point each); VKA,
vitamin K antagonist.
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Key messages
What is already known on this subject?
Atrial ﬁbrillation (AF) is associated with a ﬁvefold increase in
stroke risk. Anticoagulant (AC) therapy is known to reduce this
risk in patients with AF, but evidence shows that it is
underutilised.
What might this study add?
In this large, global, observational study of patients with newly
diagnosed non-valvular AF and ≥1 additional risk factor for
stroke, we investigated prospectively the changing pattern of
antithrombotic therapy over the past 5 years, before and after
the introduction of non-vitamin K antagonist oral ACs (NOACs).
Since the introduction of NOACs, there has been an increase in
newly diagnosed patients with AF at risk of stroke receiving
guideline-recommended therapy, predominantly driven by
increased use of NOACs and reduced use of vitamin K
antagonists±antiplatelet therapy or antiplatelet therapy alone.
How might this impact on clinical practice?
The acceptance of AC therapy in AF among physicians is a
positive step. However, there has been no change in the
proportion of patients that receive no antithrombotic treatment,
including apparently eligible patients at high stroke risk and low
bleeding risk.
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